Otsuka Pharmaceutical Company has reported promising results from its Phase 3 trial of Sibeprenlimab, a treatment for immunoglobulin A nephropathy (IgAN). The study showed a statistically significant and clinically meaningful reduction in proteinuria, with over 50% of patients experiencing a decrease. This news comes as Otsuka faces off against rival Vera Pharmaceuticals, which also has an IgAN drug in late-stage development.
Otsuka’s Sibeprenlimab demonstrated its effectiveness in reducing protein levels in the urine by more than half. The results from the Vision study provide a significant boost to the company’s stock price, with shares skyrocketing on the news.
Vera Pharmaceuticals’ IgAN treatment also showed promising results in a late-stage trial, but Otsuka’s data may give it an edge in the market. As both companies vie for dominance in the kidney disease therapy space, investors are watching closely to see how this plays out.
The announcement comes as part of Otsuka Pharmaceutical Development & Commercialization’s pre-specified interim analysis of the Phase 3 Vision study. The results will be subject to further review by regulatory agencies and may lead to FDA approval and subsequent commercialization of Sibeprenlimab.
Source: https://www.marketscreener.com/quote/stock/OTSUKA-HOLDINGS-CO-LTD-7997188/news/Otsuka-s-kidney-disease-therapy-trial-results-heat-up-battle-with-rival-Vera-50177574